Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1963-1969

  Li, Xiaoqin ^a   Liu, Shan ^a   Gu, Hangang ^a   Wang, Deqiang ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Erlotinib; Gefitinib; Median survival time; Non small cell lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB;

ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870428547     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1278-z     Document Type: Article

References (31)

1. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P (2000) Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer. Lancet 356: 373-378 (Pubitemid 30487493)
2. Coate LE, John T, Tsao MS, Shepherd FA (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10: 1001-1010
3. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047 (Pubitemid 30162806)
4. Douillard JY, Shepherd FA, Hirsh V et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752
5. Eisenhauer EA (2007) Response evaluation: beyond RECIST. Ann Oncol Suppl 9:i29-i32
6. Gridelli C, Ciardiello F, Feld R et al (2010) International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line (E) in advanced non-small-cell lung cancer (aNSCLC): the TORCH trial. J Clin Oncol 28:540s (abstr 7508)
7. Inoue A, Kobayashi K, Maemondo M et al (2009) A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. Eur J Cancer Suppl 7:6
8. Inoue A, Kobayashi K, Maemondo M, et al (2011) Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J Clin Oncol 29:2011 (suppl; abstr 7519)
9. Jaffe CC (2006) Measures of response: RECIST, WHO and new alternatives. J Clin Oncol 24: 3245-3251 (Pubitemid 46622065)
10. Johnson JR, Williams G, Pazdur R (2003) End points and United States food and drug. Administration approval of oncology drugs. J Clin Oncol 21: 1404-1411 (Pubitemid 46606423)
11. Johnson KR, Ringland C, Stokes BJ et al (2006) Response rate or time to progression as predictors of survival in trials of metastatic colo-rectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7: 741-746 (Pubitemid 44283658)
12. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19: 265-272 (Pubitemid 32063505)
13. Kurata T, Matsuo K, Takada M et al (2006) Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol 1: 684-691 (Pubitemid 47163957)
14. Lara PN Jr, Redman MW, Kelly K et al (2008) Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest oncology group randomized trials. J Clin Oncol 26: 463-467 (Pubitemid 351171700)
15. Lee JS, Park K, Kim S-W, et al (2009) A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcit-abine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4, (suppl 1; abstr PRS 4)
16. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139 (Pubitemid 38637993)
17. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957
18. Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20:42S-46S
19. Paesmans M, Sculier JP, Libert P et al (1997) Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European lung cancer working party. Eur J Cancer 33: 2326-2332 (Pubitemid 28129171)
20. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500 (Pubitemid 38720929)
21. Pantaleo MA, Nannini M, Lopci E et al (2008) Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. A collection of cases. Int J Oncol 33: 443-452
22. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nat Acad Sci USA 101: 13306-13311 (Pubitemid 39209661)
23. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431-440 (Pubitemid 19105891)
24. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343: 905-914
25. Sargent D, Shi Q, Yothers G et al (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-996
26. Sekine I, Tamura T, Kunitoh H et al (1999) Progressive disease rate as a surrogate end point of phase II trials for non-small-cell lung cancer. Ann Oncol 10: 731-733 (Pubitemid 29342381)
27. Shepherd FA (2011) Molecular selection trumps clinical selection. J Clin Oncol 29: 2843-2844
28. Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568 (Pubitemid 350035313)
29. Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J (2004) Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol 34: 717-721 (Pubitemid 41615267)
30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92: 205-216
31. Tsujino K, Kawaguchi T, Kubo A et al (2009) response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4: 994-1001.